47 results about "Hyponatremia" patented technology

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

A nutritional composition in gel form containing carbohydrates, electrolytes, anti-oxidants, vitamins and amino acids for increasing available energy during exercise, for replenishing electrolytes that are depleted during exercise, for promoting fluid retention during exercise, for preventing hyponatremia during exercise and for facilitating intestinal reabsorption of fluids during exercise. The primary electrolyte ion is sodium (Na.sup.+) compounds is in an amount such that the sodium content of the gel is in a ratio in the range of 0.4 to 1.2 parts of the sodium to 100.0 parts of the carbohydrates.

The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a beta-blocker and to combinations useful therefor. The methods, compositions and combinations of the present invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke). The methods, compositions and combinations of the present invention can also be used for the treatment and / or prevention of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin inappropriate secretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokalemia, polycystic kidney disease, diabetes, or circulation disorder.

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

The present invention relates to the cloning and characterization of a human serine / threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and / or in "macromolecular crowding" in the body, such as, for example, hypernatremia, hyponatremia, diabetes mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.

The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.

The present invention relates to the cloning and characterization of a human serine / threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and / or in “macromolecular crowding” in the body, such as, for example, hypernatremia, hyponatremia, diabetes mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.

Disclosed in the present invention is a sodium pyruvate oral rehydration salt composition for treating hypovolemia or hyponatration associated with hypohydration, said composition containing the following components: (i) 2.0-6.0 parts by weight of sodium pyruvate; (ii) 1.5-17.0 parts by weight of sodium chloride; (iii) 0-2.0 parts by weight of potassium chloride; and (iv) 10.0-50.0 parts by weight of glucose anhydrous or other carbohydrates. The weight of components (i)+(ii)+(iii)+(iv) constitutes 50-100% of the total weight of the composition.

The invention relates to the field of medicinal chemistry, and discloses a conivaptan-hydrochloride novel crystal form and a preparation method of the conivaptan-hydrochloride novel crystal form. The conivaptan-hydrochloride novel crystal form is single in crystal form, high in purity, good in stability, high in solubility and bioavailability, capable of restraining arginine vasopressin V1a and V2 receptors, and capable of being used for preparing medicine for treating hyponatremia. The preparation method of the conivaptan-hydrochloride novel crystal form is simple to operate, avoids complex and fussy crystallization processing conditions, enables solvents to be recycled, is low in production cost, and is suitable for industrial production. Products meet medicinal standards and good in stability.

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and / or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

Methods are provided for treating hyponatremia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and / or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor, optionally with a supply of carbohydrate, and / or a combination of an SGLT2 inhibitor and a diuretic agent are provided in the instant invention and are provided for use in the inventive methods.

The invention provides a dairy product drink and a preparation method thereof and relates to the field of food processing. The dairy product drink contains 10-20 parts by weight of pure milk and 101 parts by weight of yoghourt. The preparation method comprises the following preparation steps: sterilizing, cooling, removing milk skin, inoculating, fermenting, demulsifying, re-fermenting, mixing, sterilizing, cooling and encapsulating. The dairy product drink and the preparation method thereof provided by the invention have the benefits that the original-flavored dairy product drink is made by using common pure milk, does not contain harmful additive and can eliminate multifaceted health problems caused by improper use of a food additive; the dairy product drink is suitable for a wide range of people, has the efficacies of enhancing immunity, nourishing stomach, realizing high protein blood fat removal and blood pressure reduction, strengthening brain, calming nerves, relieving restlessness, improving eyesight, moistening intestine, beautifying and caring skin, and can relieve tension fatigue, dry eye soreness, fatigue, eye fatigue, chronic fatigue syndrome, osteoporosis in the aged, hyponatremia in the aged, postmenopausal osteoporosis and other symptoms.

An application of scutellaria baicalensis in preparing a medicament for treating ascites due to cirrhosis relates to a novel application of the scutellaria baicalensis. The invention aims at providing a novel application of the scutellaria baicalensis, and particularly relates to the application of the scutellaria baicalensis in a medicament for treating ascites due to cirrhosis, a medicament for treating liver function damage, a medicament for treating hepatic fibrosis, a medicament for treating liver tissue damage, a medicament for treating hypoproteinemia and a medicament or treating cholestasis. Compared with a modern therapy method, the application of the scutellaria baicalensis has the advantage that the complications, such as hepatic encephalopathy, renal function damage, hyponatremia, hypokalemia or hyperkalemia and the like are avoided, also has the advantages of low treatment cost, simple use method, ideal treatment effect and the like and is conductive to clinical practical application. The scutellaria baicalensis is used for treating ascites due to cirrhosis.

The invention belongs to the field of anti heart failure drugs, and more specifically, relates to lixivaptan crystal form I and a preparation method and use of a pharmaceutical composition containing the lixivaptan crystal form I in preparation of drugs for treating hyponatremia. The lixivaptan crystal form I is prepared from 2-chloro-4-nitro benzoic acid as a starting material by esterification, hydrogenation reduction, acylation, hydrolysis, acyl chlorination and other reaction steps, and the prepared lixivaptan purity is 97.5%. The lixivaptan crystal form I and its powder are characterized by X ray diffraction diagrams, and the lixivaptan crystal form I is important for obtaining of compounds with high purity, very determined crystal form and good reproducibility due to good prospects for development and pharmaceutical value of the lixivaptan crystal form I.

The invention belongs to the field of anti-heart failure drugs, and more particularly relates to a lixivaptan crystal form II and a preparation method thereof, a drug composition containing the lixivaptan crystal form II, and a use of the lixivaptan crystal form II in preparation of hyponatremia treatment drugs. According to the present invention, 2-chloro-4-nitrobenzoic acid is adopted as a starting raw material, and esterification, hydrogenation reduction, acylation, hydrolysis, chlorination and other reaction steps are performed to prepare the lixivaptan crystal form II, wherein the purity of the obtained lixivaptan is 97.5%, and the lixivaptan crystal form II is characterized by the powder X-ray diffraction pattern; and due to the good development prospects and the pharmaceutical values of the compound, it is important to obtain the compound with characteristics of high purity, determined crystal form and good reproducibility.

The invention provides a uterine cavity perfusate recovery and metering, tissue specimen collection and pollution protection device. The uterine cavity perfusate recovery and metering, tissue specimen collection and pollution protection device comprises a funnel body, an upper patch and a lower patch connected with the upper patch. An operation opening is formed in the connecting position of the upper patch and the lower patch, the front edge of the funnel body is connected to the lower part of the operation opening, and a neck tying belt is arranged on the rear edge of the funnel body. Gum is arranged on the sides, away from the funnel body, of the upper patch and the lower patch, and a liquid storage bag with scales is arranged at a ventage of the funnel body. According to the uterine cavity perfusate recovery and metering, tissue specimen collection and pollution protection device, the absorption amount of the perfusate can be accurately obtained, and potential serious risks can be found and treated in time, so that the occurrence of body fluid overload and / or dilution hyponatremia caused by the fact that a large amount of perfusate is absorbed is prevented; operative complications are reduced, and important clinical significance for reducing medical accidents and protecting the life safety of a patient is achieved; and moreover, specimens can be effectively collected, specimen loss is prevented, perfusate splashing pollution is prevented, and high popularization value is achieved.

The invention discloses a stomach cleaning combined reagent used for the gastroenterology department. The stomach cleaning combined reagent comprises the following ingredients in parts by weight: 10-20 parts of panax notoginseng, 3-9 parts of radix astragali, 5-15 parts of radix codonopsis, 10-15 parts of Mangnolia officinalis, 8-12 parts of radix glycyrrhizae, 5-15 parts of rhizoma corydalis, 12-20 parts of cistanche salsa, 10-15 parts of bitter gourds, 3-8 parts of honeysuckles, 5-10 parts of endothelium corneum gigeriae galli, 8-10 parts of chrysanthemums, 5-10 parts of fructus forsythia, 3-7 parts of royal jelly, 2-8 parts of honey, 5-10 parts of rhizoma cyperi, 5-15 parts of fresh ginger, 10-15 parts of barleys, 50-100 parts of normal saline and 50-100 parts of 10% potassium chloride.Compared with the prior art, the stomach cleaning combined reagent has the beneficial effects that the incidence rate of complications, that is the incidence rate of hyponatremia and hypokalemia in astomach cleaning process can be reduced; meanwhile, the stomach cleaning combined reagent has an effect of nursing a stomach and is beneficial to later recovery of the stomach.

The invention discloses a rehydration salt composition for preventing labor type heatstroke, and belongs to the technical field of combination of Chinese and western medicines. The rehydration salt composition is prepared from the following raw materials in parts by weight: 0.585 part of sodium chloride, 0.13 part of potassium chloride, 0.0215 part of calcium citrate malate, 0.9785 part of anhydrous dextrose, 0.06 part of DL-malic acid, 0.025 part of sucralose, 0.9785 part of citric acid juice powder, 0.2 part of agastache rugosus extract and 0.1 part of pericarpium citri reticulatae extract. The rehydration salt composition has good taste, and is beneficial to high-intensity training of water and salt supplement compliance; after water and salt are supplemented, the blood volume in the body is increased, hyponatremia is reduced, the sweating amount can be increased, the heat dissipation capacity of the body is improved, and heatstroke and heat stroke caused by excessive temperature rise are avoided; and the traditional Chinese medicine, namely the agastache rugosus has the effect of preventing heatstroke, and the pericarpium citri reticulatae has the effects of promoting water absorption and reducing gastrointestinal discomfort.

The invention relates to the technical field of medicines, and in particular relates to a traditional Chinese medicine for treating hyperuricemia complicated with joint swelling. The traditional Chinese medicine is prepared from the following medicinal materials in parts by weight: 20-30 parts of folium isatidis, 20-30 parts of dandelion, 20-30 parts of notopterygium root, 15-25 parts of herba potentillae discoloris cum radice, 15-25 parts of cortex moutan, 13-17 parts of rhizoma anemarrhenae, 13-17 parts of herba centellae, 10-20 parts of indigo naturalis, 10-20 parts of herba houttuyniae, 10-20 parts of fructus trichosanthis, 15-19 parts of radix paeoniae rubra, 12-18 parts of rhizoma atractylodis, 11-17 parts of rhizoma coptidis, 10-14 parts of rhizoma smilacis glabrae, 10-14 parts of rhizoma polygoni cuspidati, 10-14 parts of radix notoginseng, 10-14 parts of black soya beans, 11-17 parts of rhizoma cyperi, 10-18 parts of radix saposhnikoviae, 10-22 parts of herba artemisiae annuae, 5-9 parts of herba plantaginis, and 3-7 parts of licorice root. For the traditional Chinese medicine for treating hyperuricemia complicated with joint swelling, through scientific mixing, the ingredients achieve a synergic effect, so that the traditional Chinese medicine can promote the discharge of uric acid, supplement the elements including sodium, potassium, calcium, zinc and the like, and prevent the side reactions including hyponatremia, hypokalemia, hypocalcemia and the like, and also has the efficacies of relieving swelling and pain, regulating Qi and blood, clearing damp and dissolving turbidity, and treating arthritis.

The disclosure relates to an improved composition of a mixture based on urea. The present disclosure can be broadly described as a more stable powder composition comprising an amount of urea effective for treatment of hyponatremia. The present disclosure is a urea formulation that is a sparkling Urea (may be referred to below as "UreaAide sparkling"). The usual starting dose of urea is 15 grams, twice a day. The UreaAide sparkling is a powder that can come in single use urea dose packet. In one embodiment, the UreaAide sparkling is a single use, 15 gram urea dose packet. The 15 gram urea dosage may vary. For example, the urea dosage may not be a 15 gram dose. The urea dose can be prescribed to be taken once per day or many times throughout the day.

The invention discloses an application of FGF10 (fibroblast growth factor 10) in preparation of a medicine for treating hyponatremia, and experimental results show that the FGF10 is used for reducing the concentration of septidin in serum so as to increase the concentration of blood sodium in the serum and can be used for treating the hyponatremia.

The invention belongs to the field of anti-heart failure drugs, and more particularly relates to a lixivaptan crystal form II and a preparation method thereof, a drug composition containing the lixivaptan crystal form II, and a use of the lixivaptan crystal form II in preparation of hyponatremia treatment drugs. According to the present invention, 2-chloro-4-nitrobenzoic acid is adopted as a starting raw material, and esterification, hydrogenation reduction, acylation, hydrolysis, chlorination and other reaction steps are performed to prepare the lixivaptan crystal form II, wherein the purity of the obtained lixivaptan is 97.5%, and the lixivaptan crystal form II is characterized by the powder X-ray diffraction pattern; and due to the good development prospects and the pharmaceutical values of the compound, it is important to obtain the compound with characteristics of high purity, determined crystal form and good reproducibility.

The present invention involves novel urea compositions for oral administration, that are useful for treatment or management of hyponatremia that can be packaged in multi-use containers.

The invention relates to the field of medicinal chemistry, and discloses a conivaptan-hydrochloride novel crystal form and a preparation method of the conivaptan-hydrochloride novel crystal form. The conivaptan-hydrochloride novel crystal form is single in crystal form, high in purity, good in stability, high in solubility and bioavailability, capable of restraining arginine vasopressin V1a and V2 receptors, and capable of being used for preparing medicine for treating hyponatremia. The preparation method of the conivaptan-hydrochloride novel crystal form is simple to operate, avoids complex and fussy crystallization processing conditions, enables solvents to be recycled, is low in production cost, and is suitable for industrial production. Products meet medicinal standards and good in stability.

The present invention relates to novel oral urea compositions useful for the treatment or management of hyponatremia. Novel methods for making the urea compositions are also disclosed.

The present invention involves novel urea compositions for oral administration, that are useful for treatment or management of hyponatremia that can be packaged in multi-use containers.

A method for preventing unwanted side effects associated with the administration stimulant laxative such as bisacodyl or sodium picosulphate by orally administering sodium chloride to the patient is disclosed. Said side effects include hyponatraemia, hypokalemia, unwanted fluctuations in blood pressure, hypotension and renal failure. In certain embodiments, the sodium chloride is administered in the form of tablets during the two hours period following the administration of the stimulant laxative. This method is particularly useful in preparing patients for a colonoscopy.

Disclosed herein are compositions of urea, such as edible urea compositions for the treatment of hyponatremia. Further disclosed herein are methods for preparing such compositions of edible urea. Also disclosed are methods for administering the disclosed compositions to a subject in need thereof, such as a subject suffering from hyponatremia.